Capsule formulations
AssigneeChemoCentryx, Inc.
InventorsManmohan Reddy Leleti, Jay P. Powers
Life of this patent
Estimating the term…
Abstract
The present disclosure provides solid solution capsule formulations of Compound 1 and methods of making the same. Also provided herein are methods of treating individuals suffering from or susceptible to a disease or disorder involving pathologic activation of C5a receptors by administering an effective amount of one or more solid solution capsules comprising Compound 1. Further provided herein are singe unit dosage capsules comprising certain amounts of Compound 1, and kits comprising a solid solution capsule comprising Compound 1.
Claims18
A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form, or in the form of a pharmaceutically acceptable salt
- and a vehicle comprising
- at least one non-ionic surfactant selected from the group consisting of macrogol-40-glycerol hydroxystearate, macrogolglycerol ricinoleate, and macrogol-15-hydroxystearate, and
- at least one water-soluble solubilizer selected from the group consisting of PEG-1500, PEG-1540, PEG-2000, PEG-3000, PEG-3350, PEG-4000, PEG-6000, PEG-8000,
- wherein
- Compound 1 comprises about 1 to 3% by weight of the total fill weight of said solid solution capsule formulation, the vehicle comprises about 97 to 99% by weight of the total fill weight of said solid solution capsule formulation, and
- the total weight of the vehicle comprises a 45:55 to 55:45 ratio of the at least one non-ionic surfactant to the at least one water-soluble solubilizer.
Dependencies are inferred from the claim text.